Monkeypox: Single dose of smallpox vaccine offers 78% protection, UKHSA reports

A single dose of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic) smallpox vaccine provides around 78% protection against monkeypox 14 days after vaccination, the UK Health Security Agency (UKHSA) has said.1The agency’s analysis, released as a preprint, looked at monkeypox cases in England and vaccination uptake data from 4 July to 3 November 2022 in the eligible gay, bisexual, and men who have sex with men (GBMSM) cohort.Of 363 cases in this period, eight people had been vaccinated at least 14 days before, and 32 had been vaccinated 0-13 days before. The remaining 323 had not been vaccinated during this outbreak, giving an estimated vaccine effectiveness of 78%.The agency said that this was the “strongest UK evidence yet for the effectiveness of the vaccine,” which is sold as Imvanex in the UK and EU and as Jynneos in the US. Currently, the UK is providing a single dose of the vaccine…
Read Original Article: Monkeypox: Single dose of smallpox vaccine offers 78% protection, UKHSA reports »